Compare CIA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIA | ADAG |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.9M | 254.4M |
| IPO Year | 1995 | 2020 |
| Metric | CIA | ADAG |
|---|---|---|
| Price | $5.23 | $3.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 67.1K | ★ 151.8K |
| Earning Date | 05-07-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $255,616,000.00 | N/A |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $28.23 | ★ N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.25 | $1.44 |
| 52 Week High | $6.40 | $4.75 |
| Indicator | CIA | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 45.25 |
| Support Level | $5.09 | $3.40 |
| Resistance Level | $5.59 | $3.99 |
| Average True Range (ATR) | 0.26 | 0.28 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 35.03 | 54.48 |
Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.